Ovarian cancer stem cells express ROR1, which can be targeted for anti -cancer-stem-cell therapy

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 48, 2014, Pages 17266-17271

  Zhang, Suping ^a   Cui, Bing ^a   Lai, Hsien ^a   Liu, Grace ^a   Ghia, Emanuela M ^a   Widhopf, George F ^a   Zhang, Zhuhong ^a   Wu, Christina C N ^a   Chen, Liguang ^a   Wu, Rongrong ^a   Schwab, Richard ^a   Carson, Dennis A ^a   Kipps, Thomas J ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Monoclonal antibody |; Ovarian cancer stem cell |; PDX mice model; ROR1|

Indexed keywords

MUS;

MONOCLONAL ANTIBODY; RECEPTOR TYROSINE KINASE LIKE ORPHAN RECEPTOR; ROR1 PROTEIN, HUMAN;

ANIMAL; CANCER STEM CELL; CONFOCAL MICROSCOPY; DRUG EFFECTS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOBLOTTING; IMMUNOLOGY; KAPLAN MEIER METHOD; KNOCKOUT MOUSE; METABOLISM; MOLECULARLY TARGETED THERAPY; MULTICELLULAR SPHEROID; NONOBESE DIABETIC MOUSE; OVARIAN NEOPLASMS; PATHOLOGY; PROCEDURES; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SCID MOUSE; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOBLOTTING; KAPLAN-MEIER ESTIMATE; MICE, INBRED NOD; MICE, KNOCKOUT; MICE, SCID; MICROSCOPY, CONFOCAL; MOLECULAR TARGETED THERAPY; NEOPLASTIC STEM CELLS; OVARIAN NEOPLASMS; PROGNOSIS; RECEPTOR TYROSINE KINASE-LIKE ORPHAN RECEPTORS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SPHEROIDS, CELLULAR; TRANSPLANTATION, HETEROLOGOUS;

EID: 84914140232     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1419599111     Document Type: Article

References (50)

1. McGuire WP, et al. (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334(1):1-6.
2. Bookman MA, et al. (1996) Carboplatin and paclitaxel in ovarian carcinoma: A phase I study of the Gynecologic Oncology Group. J Clin Oncol 14(6):1895-1902.
3. Pliarchopoulou K, Pectasides D (2011) Epithelial ovarian cancer: Focus on targeted therapy. Crit Rev Oncol Hematol 79(1):17-23.
4. Clarke MF, et al. (2006) Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 66(19):9339-9344.
5. Alvero AB, et al. (2009) Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance. Cell Cycle 8(1):158-166.
6. Curley MD, Garrett LA, Schorge JO, Foster R, Rueda BR (2011) Evidence for cancer stem cells contributing to the pathogenesis of ovarian cancer. Front Biosci (Landmark Ed) 16:368-392.
7. Baba T, et al. (2009) Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Oncogene 28(2):209-218.
8. CurleyMD, et al. (2009) CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. Stem Cells 27(12):2875-2883.
9. Landen CN, Jr, et al. (2010) Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Mol Cancer Ther 9(12):3186-3199.
10. Deng S, et al. (2010) Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers. PLoS ONE 5(4):e10277.
11. Penumatsa K, Edassery SL, Barua A, Bradaric MJ, Luborsky JL (2010) Differential expression of aldehyde dehydrogenase 1a1 (ALDH1) in normal ovary and serous ovarian tumors. J Ovarian Res 3:28.
12. Yoshida A, Rzhetsky A, Hsu LC, Chang C (1998) Human aldehyde dehydrogenase gene family. Eur J Biochem 251(3):549-557.
13. Alison MR, Lim SM, Nicholson LJ (2011) Cancer stem cells: Problems for therapy? J Pathol 223(2):147-161.
14. Szotek PP, et al. (2006) Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. Proc Natl Acad Sci USA 103(30):11154-11159.
15. Moserle L, et al. (2008) The side population of ovarian cancer cells is a primary target of IFN-alpha antitumor effects. Cancer Res 68(14):5658-5668.
16. Vathipadiekal V, et al. (2012) Identification of a potential ovarian cancer stem cell gene expression profile from advanced stage papillary serous ovarian cancer. PLoS ONE 7(1):e29079.
17. Wang YC, et al. (2012) ALDH1-bright epithelial ovarian cancer cells are associated with CD44 expression, drug resistance, and poor clinical outcome. Am J Pathol 180(3): 1159-1169.
18. Zhang S, et al. (2008) Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res 68(11):4311-4320.
19. Ferrandina G, et al. (2009) CD133 antigen expression in ovarian cancer. BMC Cancer 9: 221.
20. Abubaker K, et al. (2013) Short-term single treatment of chemotherapy results in the enrichment of ovarian cancer stem cell-like cells leading to an increased tumor burden. Mol Cancer 12:24.
21. Davidowitz RA, et al. (2014) Mesenchymal gene program-expressing ovarian cancer spheroids exhibit enhanced mesothelial clearance. J Clin Invest 124(6):2611-2625.
22. Liao J, et al. (2014) Ovarian cancer spheroid cells with stem cell-like properties contribute to tumor generation, metastasis and chemotherapy resistance through hyp-oxia-resistant metabolism. PLoS ONE 9(1):e84941.
23. Ben-Porath I, et al. (2008) An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 40(5):499-507.
24. Schwede M, et al. (2013) Stem cell-like gene expression in ovarian cancer predicts type II subtype and prognosis. PLoS ONE 8(3):e57799.
25. Scheel C, Weinberg RA (2012) Cancer stem cells and epithelial-mesenchymal transition: Concepts and molecular links. Semin Cancer Biol 22(5-6):396-403.
26. Fukuda T, et al. (2008) Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a. Proc Natl Acad Sci USA 105(8):3047-3052.
27. Rabbani H, et al. (2010) Expression of ROR1 in patients with renal cancer: A potential diagnostic marker. Iran Biomed J 14(3):77-82.
28. Barna G, et al. (2011) ROR1 expression is not a unique marker of CLL. Hematol Oncol 29(1):17-21.
29. Gentile A, Lazzari L, Benvenuti S, Trusolino L, Comoglio PM (2011) Ror1 is a pseudokinase that is crucial for Met-driven tumorigenesis. Cancer Res 71(8):3132-3141.
30. Zhang S, et al. (2012) The onco-embryonic antigen ROR1 is expressed by a variety of human cancers. Am J Pathol 181(6):1903-1910.
31. Zhang S, et al. (2012) ROR1 is expressed in human breast cancer and associated with enhanced tumor-cell growth. PLoS ONE 7(3):e31127.
32. Yamaguchi T, et al. (2012) NKX2-1/TITF1/TTF-1-Induced ROR1 is required to sustain EGFR survival signaling in lung adenocarcinoma. Cancer Cell 21(3):348-361.
33. Cui B, et al. (2013) Targeting ROR1 inhibits epithelial-mesenchymal transition and metastasis. Cancer Res 73(12):3649-3660.
34. Zhang H, et al. (2014) ROR1 expression correlated with poor clinical outcome in human ovarian cancer. Sci Rep 4:5811.
35. Tothill RW, et al.; Australian Ovarian Cancer Study Group (2008) Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 14(16):5198-5208.
36. Bonome T, et al. (2008) A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. Cancer Res 68(13):5478-5486.
37. Subramanian A, et al. (2005) Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102(43):15545-15550.
38. Park IK, Morrison SJ, Clarke MF (2004) Bmi1, stem cells, and senescence regulation. J Clin Invest 113(2):175-179.
39. Kreso A, et al. (2014) Self-renewal as a therapeutic target in human colorectal cancer. Nat Med 20(1):29-36.
40. Widhopf GF, 2nd, et al. (2014) ROR1 can interact with TCL1 and enhance leukemogenesis in Eμ-TCL1 transgenic mice. Proc Natl Acad Sci USA 111(2):793-798.
41. Winter WE, 3rd, et al.; Gynecologic Oncology Group Study (2007) Prognostic factors for stage III epithelial ovarian cancer: A Gynecologic Oncology Group Study. J Clin Oncol 25(24):3621-3627.
42. Rizzo S, et al. (2011) Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2. Mol Cancer Ther 10(2):325-335.
43. Vinogradov S, Wei X (2012) Cancer stem cells and drug resistance: The potential of nanomedicine. Nanomedicine (Lond) 7(4):597-615.
44. Ricci F, et al. (2013) ALDH enzymatic activity and CD133 positivity and response to chemotherapy in ovarian cancer patients. Am J Cancer Res 3(2):221-229.
45. Silva IA, et al. (2011) Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. Cancer Res 71(11):3991-4001.
46. Bauer N, et al. (2008) New insights into the cell biology of hematopoietic progenitors by studying prominin-1 (CD133). Cells Tissues Organs 188(1-2):127-138.
47. Arber DA, Tamayo R, Weiss LM (1998) Paraffin section detection of the c-kit gene product (CD117) in human tissues: Value in the diagnosis of mast cell disorders. Hum Pathol 29(5):498-504.
48. Slomiany MG, et al. (2009) Inhibition of functional hyaluronan-CD44 interactions in CD133-positive primary human ovarian carcinoma cells by small hyaluronan oligosaccharides. Clin Cancer Res 15(24):7593-7601.
49. Casagrande F, et al. (2011) Eradication of chemotherapy-resistant CD44+ human ovarian cancer stem cells in mice by intraperitoneal administration of Clostridium perfringens enterotoxin. Cancer 117(24):5519-5528.
50. Broome HE, Rassenti LZ, Wang HY, Meyer LM, Kipps TJ (2011) ROR1 is expressed on hematogones (non-neoplastic human B-lymphocyte precursors) and a minority of precursor-B acute lymphoblastic leukemia. Leuk Res 35(10):1390-1394.